MedTrace Logo

Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas

NCT00493467 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2022-09-15

Study results available
· View outcomes & findings →

Summary

The goal of this clinical research study is to find out if giving (Rituxan) rituximab with 90Y (ibritumomab tiuxetan) (90 Y Zevalin®) may be effective in treating low-grade lymphoma. The safety of this combination treatment will also be studied.

Conditions

Interventions

DRUG

Ibritumomab Tiuxetan (Zevalin)

111In Zevalin (5 mCi of \^111In, 1.6 mg of Ibritumomab Tiuxetan) Intravenously Over 10 minutes on Day 1. 90Y Zevalin 0.3 or 0.4 mCi/kg Intravenously Over 10 minutes on Day 8.

DRUG

Rituximab

250 mg/m\^2 Intravenously Over 4-6 Hours On Days 1 and 8.

Sponsors & Collaborators

  • Biogen

    collaborator INDUSTRY

  • CTI BioPharma

    collaborator INDUSTRY

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Felipe Samaniego, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2015-04-30
Completion
2022-08-11

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00493467 on ClinicalTrials.gov